Vanda Pharmaceuticals Expands Fanapt Franchise with Novel Indication
Vanda Pharmaceuticals (VNDA) has announced a significant milestone as the U.S. Food and Drug Administration (FDA) approves Fanapt (iloperidone) tablets for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This approval marks a substantial expansion of Fanapt’s utility beyond its previous use in schizophrenia treatment since 2009.
Bipolar disorder affects approximately 2.8% of the U.S. adult population, with severe cases impacting 83%. With Fanapt now approved for bipolar I disorder, patients and healthcare providers gain a new treatment option backed by over 100,000 patient years of experience. The approval underscores Vanda’s commitment to addressing high unmet medical needs and improving patient outcomes.
Dr. Mihael H. Polymeropoulos, Vanda’s President, CEO, and Chairman of the Board, emphasized the complexity of manic or mixed episodes associated with bipolar I disorder and the need for trusted treatment options tailored to individual patient needs. The approval of Fanapt represents a pivotal advancement in managing bipolar disorder and reflects Vanda’s dedication to innovation and patient-centric care.
Read original press release:here
You might like this article:Amazon’s AWS Division Implements Layoffs Amidst Shifting Market Dynamics
